23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.
23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.
ME
2.28 as of 3/21/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 12/23/2020 | Series F-1 | $2.59B | $XXX.XX | $XXX.XX |
| 9/12/2017 | Series F | $1.75B | $XXX.XX | $XXX.XX |
| 6/8/2015 | Series E | $1.1B | $XXX.XX | $XXX.XX |
| 12/10/2012 | Series D | $288.74MM | $XXX.XX | $XXX.XX |
| 11/10/2010 | Series C | $184.5MM | $XXX.XX | $XXX.XX |
| 12/23/2009 | Series B | $150.5MM | $XXX.XX | $XXX.XX |
| 5/22/2007 | Series A | $48.5MM | $XXX.XX | $XXX.XX |
